Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders

References

• Kessler RC, Chiu WT, Demler O et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62(6), 617–627 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry62(6), 593–602 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Brandenburg N, Lane M et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol. Med.35(7), 1073–1082 (2005).
   PubMed Web of Science ®Google Scholar
• Grant BF, Hasin DS, Stinson FS et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the national epidemiologic survey on alcohol and related conditions. Psychol. Med.35(12), 1747–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Hunt C, Issakidis C, Andrews G. DSM-IV generalized anxiety disorder in the Australian national survey of mental health and well-being. Psychol. Med.32(4), 649–659 (2002).
   PubMed Web of Science ®Google Scholar
• Bruce SE, Machan JT, Dyck I et al. Infrequency of pure GAD: impact of psychiatric comorbidity on clinical course. Depress. Anxiety14(4), 219–225 (2001).
   PubMed Web of Science ®Google Scholar
• Moffitt TE, Harrington H, Caspi A et al. Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Arch. Gen. Psychiatry64(6), 651–660 (2007).
   PubMed Web of Science ®Google Scholar
• Hasin DS, Goodwin RD, Stinson FS et al. Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Arch. Gen. Psychiatry62(10), 1097–1106 (2005).
   PubMed Web of Science ®Google Scholar
• Kendler KS, Gardner CO, Gatz M et al. The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol. Med.37(3), 453–462 (2007).
   PubMed Web of Science ®Google Scholar
• Andrade L, Caraveo-Anduaga JJ, Berglund P et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int. J. Methods Psychiatr. Res.12(1), 3–21 (2003).
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Kessler RC, Beesdo K et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J. Clin. Psychiatry.63(Suppl. 8), 24–34 (2002).
   PubMed Web of Science ®Google Scholar
• Melartin TK, Rytsälä HJ, Leskelä US et al. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J. Clin. Psychiatry63(2), 126–134 (2002).
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Mulsant BH, Mohlman J et al. Generalized anxiety disorder in late life: lifetime course and comorbidity with major depressive disorder. Am. J. Geriatr. Psychiatry13(1), 77–80 (2005).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Bottas A et al. Anxiety disorders and bipolar disorder: a review. Bipolar Disord.8(6), 665–676 (2006).
   PubMed Web of Science ®Google Scholar
• Gao K, Tolliver BK, Kemp DE et al. Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J. Affect. Disord.110(1–2), 167–173 (2008).
   PubMedGoogle Scholar
• Grant BF, Stinson FS, Hasin DS et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the national epidemiologic survey on alcohol and related conditions. J. Clin. Psychiatry66(10), 1205–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Simon NM, Otto MW, Wisniewski SR et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am. J. Psychiatry161(12), 2222–2229 (2004).
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch. Gen. Psychiatry64(5), 543–552 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Levitt AJ. The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. Bipolar Disord.10(1), 67–78 (2008).
   PubMed Web of Science ®Google Scholar
• Compton WM, Thomas YF, Stinson FS et al. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry64(5), 566–576 (2007).
   PubMed Web of Science ®Google Scholar
• Kessler RC, DuPont RL, Berglund P et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry156(12), 1915–1923 (1999).
   PubMed Web of Science ®Google Scholar
• Grant BF, Hasin DS, Stinson FS et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the national epidemiologic survey on alcohol and related conditions. Psychol. Med.35(12), 1747–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Stein MB, Heimberg RG. Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample. J. Affect. Disord.79(1–3), 161–166 (2004).
   PubMed Web of Science ®Google Scholar
• Munk-Jørgensen P, Allgulander C, Dahl AA et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr. Serv.57(12), 1738–1744 (2006).
   PubMed Web of Science ®Google Scholar
• Ansseau M, Fischler B, Dierick M et al. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur. Psychiatry20(3), 229–235 (2005).
   PubMed Web of Science ®Google Scholar
• Mittal D, Fortney JC, Pyne JM et al. Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Psychiatr. Serv.57(12), 1731–1737 (2006).
   PubMed Web of Science ®Google Scholar
• Fava M, Alpert JE, Carmin CN et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol. Med.34(7), 1299–1308 (2004).
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am. J. Psychiatry165(3), 342–351 (2008).
   PubMed Web of Science ®Google Scholar
• DeLuca AK, Lenze EJ, Mulsant BH et al. Comorbid anxiety disorder in late life depression: association with memory decline over four years. Int. J. Geriatr. Psychiatry20(9), 848–854 (2005).
   PubMed Web of Science ®Google Scholar
• Otto MW, Simon NM, Wisniewski SR et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br. J. Psychiatry189, 20–25 (2006).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry163(2), 217–224 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Bose A, Korotzer A et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety19(4), 234–240 (2004).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Zaninelli R, Goddard A et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry62(5), 350–357 (2001).
   PubMed Web of Science ®Google Scholar
• Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr.9(10), 716–723 (2004).
   PubMed Web of Science ®Google Scholar
• Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J. Clin. Psychiatry66(10), 1321–1325 (2005).
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Canuso CM, Turkoz I et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol. Bull.40(3), 41–57 (2007).
   PubMedGoogle Scholar
• Pollack MH, Simon NM, Zalta AK et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol. Psychiatry59(3), 211–225 (2006).
   PubMed Web of Science ®Google Scholar
• Simon NM, Connor KM, LeBeau RT et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl.)197(4), 675–681 (2008).
   PubMed Web of Science ®Google Scholar
• Sheehan DV, McElroy SL, Harnett-Sheehan K et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J. Affect. Disord.115(3), 376-85 (2009).
   PubMedGoogle Scholar
• Brawman-Mintzer O, Nietert PJ, Rynn M et al. Quetiapine monotherapy in patients with GAD. Presented at: 159th Annual Meeting of American Psychiatric Association. Toronto, ON, Canada, 20–25 May 2006 (New Research Abstract 634).
   Google Scholar
• Chouinard G, Bandelow B, Ahokas A et al. Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder: a Phase III, double-blind, placebo-controlled study. Program of the 46th American College of Neuropsychopharmacology Annual Meeting. Boca Raton, FL, USA, 9–13 December 2007 (P25).
   Google Scholar
• Joyce M, Khan A, Atkinson S et al. Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD). Presented at: 159th Annual Meeting of American Psychiatric Association. Washington, DC, USA, 3–8 May 2008 (New Research Abstract 3138).
   Google Scholar
• Merideth C, Cutler A, Neijber A et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalized anxiety disorder. Eur. Neuropsychoparmacol.18, S499–S500 (2008).
   Web of Science ®Google Scholar
• Katzman M, Brawman-Mintzer O, Reyes E et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial). Presented at: 159th Annual Meeting of American Psychiatric Association. Washington, DC, USA, 3–8 May 2008 (New Research Abstract 3140).
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Version. American Psychiatric Association. Washington, DC, USA (2000).
   Google Scholar
• World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, Switzerland (1992).
   Google Scholar
• Hamilton M. The assessment of anxiety state by rating. Br. J. Med. Psychol.32, 50–55 (1959).
   PubMed Web of Science ®Google Scholar
• Andrews G, Slade T. The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis. Psychopathology35(2–3), 100–106 (2002).
   PubMed Web of Science ®Google Scholar
• Montgomery D. European College of Neuropsychopharmacology. ECNP Consensus Meeting March 2000. Guidelines for investigating efficacy in GAD Eur. Neuropsychopharmacol.12(1), 81–87 (2002).
   PubMedGoogle Scholar
• Rickels K, Rynn MA. What is generalized anxiety disorder? J. Clin. Psychiatry62(Suppl. 11), 4–12 (2001).
   PubMedGoogle Scholar
• Lee S, Tsang A, Chui H et al. A community epidemiological survey of generalized anxiety disorder in Hong Kong, Community Ment. Health J.43(4), 305–319 (2007).
   PubMed Web of Science ®Google Scholar
• Lee S, Tsang A, Zhang MY et al. Lifetime prevalence and inter-cohort variation in DSM-IV disorders in metropolitan China. Psychol. Med.37(1), 61–71 (2007).
   PubMedGoogle Scholar
• Carter RM, Wittchen HU, Pfister H et al. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress. Anxiety13(2), 78–88 (2001).
   PubMed Web of Science ®Google Scholar
• Cho MJ, Kim JK, Jeon HJ et al. Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults. J. Nerv. Ment. Dis.195(3), 203–210 (2007).
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. J. Clin. Psychiatry65(Suppl. 13), 20–26 (2004).
   PubMed Web of Science ®Google Scholar
• Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur. Neuropsychopharmacol.15(4), 445–452 (2005).
   PubMed Web of Science ®Google Scholar
• Brunette MF, Noordsy DL, Xie H et al. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr. Serv.54(10), 1395–1401 (2003).
   PubMed Web of Science ®Google Scholar
• Gao K. Antipsychotics in the treatment of comorbid anxiety in bipolar disorder. Psychiatr. Times24(5), 68–69 (2007).
   Google Scholar
• Olssøn I, Mykletun A, Dahl AA. Recognition and treatment recommendations for generalized anxiety disorder and major depressive episode: a cross-sectional study among general practitioners in Norway. Prim. Care Companion J. Clin. Psychiatry8(6), 340–347 (2006).
   PubMedGoogle Scholar
• Lecrubier Y. Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. J. Clin. Psychiatry.68(Suppl. 2), 36–41 (2007).
   PubMed Web of Science ®Google Scholar
• Salzman C, Goldenberg I, Bruce SE et al. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown anxiety disorders research program J. Clin. Psychiatry62(3), 149–152 (2001).
   PubMedGoogle Scholar
• Goodwin RD, Gorman JM. Psychopharmacological treatment of generalized anxiety disorder and the risk of major depression. Am. J. Psychiatry159, 1935–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Levitt AJ. Prevalence and correlates of bipolar I disorder among adults with primary youth-onset anxiety disorders. J. Affect. Disord.103(1–3), 187–195 (2007).
   PubMedGoogle Scholar
• Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder. Arch. Gen. Psychiatry62, 1022–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Lydiard RB, Rudolph RL et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA283(23), 3082–3088 (2000).
   PubMed Web of Science ®Google Scholar
• Rollman BL, Belnap BH, Mazumdar S et al. Symptomatic severity of PRIME-MD diagnosed episodes of panic and generalized anxiety disorder in primary care. J. Gen. Intern. Med.20(7), 623–628 (2005).
   PubMed Web of Science ®Google Scholar
• Stein DJ. Generalized anxiety disorder: rethinking diagnosis and rating. CNS Spectr.10(12), 930–934 (2005).
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the british association for psychopharmacology. J. Psychopharmacol.19(6), 567–596 (2005).
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry62(Suppl. 11), 53–58 (2001).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Bandelow B, Hollander E et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr.8(8 Suppl. 1), 53–61 (2003).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders :first revision. World J. Biol. Psychiatry9(4), 248–312(2008).
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Sheehan KH. Current approaches to the pharmacologic treatment of anxiety disorders. Psychopharmacol. Bull.40(1), 98–109 (2007).
   PubMedGoogle Scholar
• Gao K, Muzina D, Gajwani P et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J. Clin. Psychiatry67(9), 1327–1340 (2006).
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Potvin JH. Fluoxetine: activating and sedating effects. Int. Clin. Psychopharmacol.8(4), 271–275 (1993).
   PubMedGoogle Scholar
• Baldwin DS, Montgomery SA, Nil R et al. Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol.10(1), 73–84 (2007).
   PubMed Web of Science ®Google Scholar
• Gao K, Ganocy SJ, Gajwani P et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J. Clin. Psychiatry69(2), 302–309 (2008).
   PubMed Web of Science ®Google Scholar
• Mitte K, Noack P, Steil R et al. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J. Clin. Psychopharmacol.25(2), 141–150 (2005).
   PubMed Web of Science ®Google Scholar
• Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol.21(8), 864–872 (2007).
   PubMed Web of Science ®Google Scholar
• Pollack M, Kinrys G, Krystal A et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch. Gen. Psychiatry65(5), 551–562 (2008).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities Can.J. Psychiatry46(3), 273–281 (2001).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry68(Suppl. 1), 20–27 (2007).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry65, 267–272 (2004).
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med.360(3), 225–235 (2009).
   PubMed Web of Science ®Google Scholar
• Thase ME, Jonas A, Khan A et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol.28(1), 13–20 (2008).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am. J. Psychiatry162(7), 1351–1360 (2005).
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol.26(6), 600–609 (2006).
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry60(11), 1079–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Ruscio AM, Chiu WT, Roy-Byrne P et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the national comorbidity survey replication. J. Anxiety Disord.21(5), 662–676 (2007).
   PubMed Web of Science ®Google Scholar
• Ruscio AM, Lane M, Roy-Byrne P et al. Should excessive worry be required for a diagnosis of generalized anxiety disorder? results from the US national comorbidity survey replication. Psychol. Med.35(12), 1761–1772 (2005).
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Amiel JM, Coplan JD et al. Open-label trial of riluzole in generalized anxiety disorder. Am. J. Psychiatry162(12), 2379–2381 (2005).
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Price RB, Mao X et al. Hippocampal n-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol. Psychiatry63(9), 891–898 (2008).
   PubMed Web of Science ®Google Scholar
• Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders CNS Spectr.10(10), 820–830 (2005)
   PubMed Web of Science ®Google Scholar